On the other hand, Imeglimin, an anti-diabetic drug, improved insulin secretion and pancreatic β-cell function by increasing the number of insulin granules and reducing apoptotic β-cell death in T2DM [37,38]. The gene discussed is INS; the disease is type 2 diabetes mellitus.